AKKARAJU SRINIVAS purchased $10.7M of ALMS (indirect holdings)

AKKARAJU SRINIVAS purchased 986,721 indirectly-held shares of ALUMIS INC. (ALMS) at an average of $10.87 ($10.63–$11.17, $10.73M total) across 4 trades over 2026-09-04 to 2026-09-08.

Original reporting
SEC EDGAR · AKKARAJU SRINIVAS
Published Sep 10, 2026, 1:39 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 10, 2026, 2:05 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ALMS
Bullish
high confidence
Mentioned
$ALMS
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSBullishMed
01

Why it matters

The insider buy adds a positive data point for Alumis, potentially prompting short-term buying pressure.

02

Market read

A material insider purchase by a director can move the stock and influence investor sentiment.

03

What to watch

No disclosed 10b5-1 plan; the timing may be opportunistic based on price rather than fundamentals.

Relevance 8/10Novelty 8/10Timing: filed 2026-09-09

Background

SEC Form 4 filings disclose insider transactions; director purchases are closely watched for signals.

Company-level read

Ticker impact

$ALMSBullishHigh confidence
Context

Director Akkaraju Srivinas bought 986,721 shares of Alumis Inc. for $10.7M, increasing his stake to 2,298,783 shares.

Expected impact

Potential short-term upside as the market may view the purchase as a bullish signal.

Evidence & confidence

A $10.7M purchase by a director is material and likely to influence investor sentiment.

Market effects

May signal confidence in the specialty chemicals sector, potentially supporting peers.

Limited to US markets where Alumis trades.

Low, as the filing concerns a single mid-cap US company.

Counterpoint

The purchase could be a routine portfolio rebalancing rather than a strong endorsement.

Key entities

  • Alumis Inc.

    Specialty chemicals manufacturer listed on NYSE under ticker ALMS.

  • Akkaraju Srivinas

    Director of Alumis Inc. who executed the purchase.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ALMSMed

Alumis Reports Q3 2026 Results, $94.9 Million Net Loss

Alumis reported Q3 2026 revenue of $1.9M and a net loss of $94.9M. Cash reserves totaled $431.3M, expected to last into Q4 2027. The company plans to submit an NDA for envudeucitinib in plaque psoriasis by Q4 2026, with positive Phase 3 data for scalp psoriasis. A Phase 2b trial in lupus did not meet primary endpoints, but a subgroup showed responses. Alumis will start a Phase 2 trial for A-005 in Parkinson's in 2027.

$ALMSHigh

Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates

ALUMIS INC. (ALMS) filed an SEC Form 8-K — Results of Operations and Financial Condition. ​ Exhibit 99.1 ​ ​ Alumis Reports Third Quarter 2026 Financial Results and Highlights Recent Business Updates ​ – New Phase 3 data demonstrated rapid and durable improvements in plaque psoriasis burden, adding to envudeucitinib’s differentiated clinical profile, including the hig

$ALMSHighAI 8/10

Alumis (ALMS) Faces Pressure After Clinical Results

Voya MI Dynamic Small Cap Fund reported that its overweight position in Alumis (ALMS) hurt performance due to disappointing clinical trial results. ALMS closed at $6.62 with a $883.74M market cap, up 25.38% over 52 weeks. The fund's Q3 2026 letter cited sector performance variations, with energy, tech, and healthcare outperforming.